Why Alzheimer's Research Keeps Stalling Despite Decades of Investment

Freakonomics examines why Alzheimer’s disease has proven so resistant to therapeutic progress despite massive funding and scientific attention. The dominant amyloid hypothesis has shaped research priorities for decades, yet drugs targeting amyloid plaques have produced disappointing clinical results, raising questions about whether the field has been chasing the wrong mechanism.

The piece explores how scientific consensus can calcify around a single theory, crowding out alternative approaches and skewing grant funding toward established lines of inquiry. Researchers pursuing inflammation, vascular, or metabolic explanations have historically struggled to secure resources, even as evidence mounts that Alzheimer’s may be a heterogeneous condition requiring multiple intervention strategies.

The broader takeaway concerns how institutional incentives in biomedical research can entrench unproductive paradigms. Career risk, peer review dynamics, and the long timelines of neurodegenerative trials combine to make course corrections slow and costly, even when accumulating failures suggest the underlying model needs revision.